SCHEMBL3304205

SCHEMBL3304205

O=C1O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 2/20 0.54
ACHE P22303 2/20 0.54
LMNA P02545 1/20 0.45
HTR1A P08908 1/20 0.42
TACR2 P21452 3/20 0.42
NT5E P21589 1/20 0.42
PDPK1 O15530 1/20 0.40
MTOR P42345 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
CTRB1 P17538 1/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
FASN P49327 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7525585 1.00 BCHE (0.54) BCHEACHELMNAHTR1ATACR2
SCHEMBL14571363 1.00 BCHE (0.54) BCHEACHELMNAHTR1ATACR2
SCHEMBL13591463 1.00 BCHE (0.54) BCHEACHELMNAHTR1ATACR2
SCHEMBL30801101 1.00 BCHE (0.54) BCHEACHELMNAHTR1ATACR2
SCHEMBL18497676 1.00 BCHE (0.54) BCHEACHELMNAHTR1ATACR2
SCHEMBL18852561 1.00 BCHE (0.54) BCHEACHELMNAHTR1ATACR2
SCHEMBL7522263 1.00 BCHE (0.54) BCHEACHELMNAHTR1ATACR2
SCHEMBL12896359 1.00 BCHE (0.54) BCHEACHELMNAHTR1ATACR2
SCHEMBL22796970 1.00 BCHE (0.54) BCHEACHELMNAHTR1ATACR2
SCHEMBL1087871 0.96 BCHE (0.56) BCHEACHELMNAHTR1ATACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023126968-A1 A PROCESS FOR THE SYNTHESIS OF BCX-1777 AND BCX-4430 COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2023-07-06 WO claimed
US-11612614-B2 Isomorphs of Remdesivir and methods for synthesis of same Anzalp Pharmasolutions Pvt. Ltd. (IN) 2023-03-28 US claimed
US-20210228605-A1 ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME Anzalp Pharmasolutions Pvt. Ltd. (IN) 2021-07-29 US claimed
US-20210161927-A1 ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME Anzalp Pharmasolutions Pvt. Ltd. (IN) 2021-06-03 US claimed
US-20260000698-A1 SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS UNIV MINNESOTA (US) 2026-01-01 US disclosed
EP-4591935-A2 METHODS FOR THE PREPARATION OF RIBOSIDES Gilead Sciences, Inc. (US) 2025-07-30 EP disclosed
US-20250236623-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. 2025-07-24 US disclosed
EP-4588928-A2 METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS Gilead Sciences, Inc. (US) 2025-07-23 EP disclosed
EP-4323362-B1 METHODS OF PREPARING CARBANUCLEOSIDES USING AMIDES GILEAD SCIENCES INC (US) 2025-05-07 EP disclosed
CN-113549120-B Method for preparing ribonucleoside 吉利德科学公司 2025-04-29 CN disclosed
CN-108348526-B Methods of treating arenaviridae and coronaviridae viral infections 吉利德科学公司 2025-04-25 CN disclosed
CN-113493480-B Preparation and analysis method of Ruidexivir isomer 南京正大天晴制药有限公司 2025-04-15 CN disclosed
WO-2010093608-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-19 WO disclosed
US-20100203015-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-12 US disclosed
US-20100203015-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-08-12 US disclosed
US-20100093991-A1 METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES BIO CRYST PHARMACEUTICALS , INC. (US) 2010-04-15 US disclosed
US-20100021425-A1 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-01-28 US disclosed
US-20100021425-A1 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2010-01-28 US disclosed
WO-2009132135-A1 1' -SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2009-10-29 WO disclosed
WO-1997041140-A1 MODIFIED OLIGONUCLEOTIDES NOVARTIS AG (CH) 1997-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236623-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS SYNJ1, SARS1, SYNJ2 BCHE 4586/4885ACHE 4791/4885LMNA 2638/4885
US-20100203015-A1 CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT PNP, TYMP, MTAP BCHE 3017/4885ACHE 4145/4885LMNA 1447/4885
US-11612614-B2 Isomorphs of Remdesivir and methods for synthesis of same MTAP, SARS1, PNP BCHE 641/4885ACHE 775/4885LMNA 3614/4885
US-20100093991-A1 METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES DPYD, TYMP, UNG BCHE 1635/4885ACHE 4464/4885LMNA 970/4885
US-20100021425-A1 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT PNP, MTAP, SLC29A1 BCHE 3342/4885ACHE 4231/4885LMNA 3262/4885
US-20210228605-A1 ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME MTAP, SARS1, PNP BCHE 649/4885ACHE 799/4885LMNA 3567/4885
US-20210161927-A1 ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME MTAP, SARS1, PNP BCHE 641/4885ACHE 775/4885LMNA 3614/4885
US-20260000698-A1 SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS NSUN2, SARS1, RNMT BCHE 1688/4885ACHE 2184/4885LMNA 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.